Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.

摘要: Between August 1986 and October 1987, the Denver Brain Tumor Research Group conducted a clinical trial using autologous human recombinant interleukin-2 (rIL-2)-activated lymphocytes to treat 20 patients with recurrent high-grade gliomas. The involved surgical resection and/or decompression followed by intracavitary implantation of lymphokine-activated killer (LAK) cells stimulated (ASL) along rIL-2 in plasma clot. One month later, were infused through Rickham reservoir attached catheter directed into tumor bed. LAK rIL-2-activated peripheral blood cultured for 4 days; ASL lectin- 10 days. Of treated, 11 evaluated as group (mean age, 44 years, range, 15-61 years; mean Karnofsky rating, 69, 50-100; Decadron dose at entry, 14 mg/d, 0-32). average number implanted was 7.6 x 10(9) (range, 1.9-27.5 10(9], together 1 10(6) U rIL-2. To date, died, all from growth. median overall survival time 63 weeks 36-201; mean, 86). after immunotherapy 18 11-151; 39). No significant difference found between those who had received previous chemotherapy not. use steroids or prior did not influence vitro generation cells.(ABSTRACT TRUNCATED AT 250 WORDS)